How to Get Crestor (Rosuvastatin) in New York

Who Can Prescribe Rosuvastatin in New York

Any New York-licensed physician (MD or DO), nurse practitioner, or physician assistant can prescribe rosuvastatin. NPs in New York operate under a collaborative practice agreement for the first 3,600 hours of practice, after which they may practice independently per the New York Education Law §6902. PAs prescribe under physician supervision statewide.

MDs and DOs

Primary care physicians, internists, and cardiologists are the most common prescribers. A board-certified internist or cardiologist may be preferred if you have a history of atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia, since these conditions often require higher doses (20 mg to 40 mg) and closer lipid monitoring.

Nurse Practitioners

After completing 3,600 practice hours under a collaborative agreement, NPs in New York gain full practice authority. This means an NP can independently evaluate your lipid panel, initiate rosuvastatin, and manage ongoing dose titration without a physician co-signature. Telehealth NP visits are common for statin prescriptions.

Physician Assistants

PAs prescribe rosuvastatin under a supervising physician. The supervision does not require the physician to be physically present for each encounter, so PA-led telehealth visits remain a valid prescribing pathway.

Telehealth Access to Rosuvastatin in New York

New York State permits telehealth prescribing for rosuvastatin. This is one of the most efficient paths to a prescription, especially for patients in rural upstate counties where cardiologists are less accessible.

How a Telehealth Visit Works

A typical rosuvastatin telehealth visit lasts 10 to 20 minutes. The provider reviews your medical history, current medications, and recent lab work. If you have a lipid panel from the past 12 months showing elevated LDL-C, most providers will prescribe the same day. If labs are outdated, you will receive a lab order to complete before the prescription is issued.

Platforms That Serve New York

HealthRX and other licensed telehealth platforms connect New York residents with providers who can evaluate cardiovascular risk and prescribe statins. The 2013 ACC/AHA guideline on cholesterol management identifies four statin benefit groups, and telehealth providers follow these same criteria when determining whether rosuvastatin is appropriate. The key advantage: no commute, no waiting room, and prescriptions sent electronically to any New York pharmacy.

Prescriptions for Existing Patients

If you already take rosuvastatin and need a refill from a New York provider (for example, after relocating), a telehealth visit with documentation of your current dose and recent lipid panel is typically sufficient. Most providers will issue a 90-day prescription with refills.

Required Labs Before Starting Rosuvastatin

Rosuvastatin prescriptions in New York require baseline lab work. No responsible provider will initiate a statin without reviewing your lipid panel and liver function.

Baseline Lipid Panel

A fasting lipid panel measures total cholesterol, LDL-C, HDL-C, and triglycerides. The 2018 AHA/ACC Multisociety Guideline recommends using the 10-year ASCVD risk calculator to determine statin intensity. For patients with LDL-C above 190 mg/dL, high-intensity statin therapy (rosuvastatin 20 mg to 40 mg) is indicated regardless of calculated risk [2].

Hepatic Function Panel

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be measured before starting therapy. The FDA-approved rosuvastatin label lists active liver disease as a contraindication [3]. If ALT exceeds three times the upper limit of normal, rosuvastatin should not be initiated.

Follow-Up Labs

Repeat the lipid panel 4 to 12 weeks after starting therapy to assess LDL-C response. Rosuvastatin 10 mg typically reduces LDL-C by 45% to 52%, while the 20 mg dose achieves 48% to 55% reduction according to data from the STELLAR trial (N=2,431) [4]. If the target LDL-C is not reached, your provider may increase the dose or add ezetimibe.

Insurance Coverage and Cost in New York

The price you pay for rosuvastatin depends on whether you fill the brand (Crestor) or generic, and which insurance plan you carry.

Generic Rosuvastatin Pricing

Since patent expiration in 2016, generic rosuvastatin has been available from manufacturers including Teva, Sandoz, and Aurobindo. A 30-day supply of generic rosuvastatin 10 mg costs $8 to $25 at most New York retail pharmacies. Costco and Mark Cuban's Cost Plus Drugs often price it below $10 for 90 tablets. Cash-pay patients should compare prices across pharmacies, as markups vary significantly even within the same borough.

Brand Crestor Pricing

Brand Crestor carries a list price above $300 per month. AstraZeneca's savings card may reduce out-of-pocket costs for commercially insured patients, but Medicare and Medicaid beneficiaries are ineligible for manufacturer coupons per federal anti-kickback statute rules.

New York Medicaid

New York Medicaid covers rosuvastatin for hyperlipidemia and ASCVD prevention with prior authorization. The PA process typically requires documentation of a diagnosis code (ICD-10 E78.0 for pure hypercholesterolemia or E78.5 for dyslipidemia), a recent lipid panel showing elevated LDL-C, and confirmation that the patient meets statin benefit group criteria. Approval turnaround is generally 24 to 72 hours.

Commercial Insurance

Most commercial plans in New York (Empire BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, Oxford) place generic rosuvastatin on Tier 1 or Tier 2 with copays of $0 to $15. Brand Crestor typically sits on Tier 3 or requires a non-preferred brand exception. The JUPITER trial (N=17,802) demonstrated a 44% relative risk reduction in the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death with rosuvastatin 20 mg versus placebo [1]. This strong evidence base means most insurers approve rosuvastatin without step therapy requirements for the generic.

Medicare Part D

Medicare Part D plans in New York almost universally cover generic rosuvastatin. During the coverage gap (donut hole), beneficiaries pay no more than 25% coinsurance for generic drugs under the Inflation Reduction Act provisions. The $2,000 annual out-of-pocket cap that took effect in 2025 further limits statin costs for Medicare enrollees.

Prior Authorization in New York

Prior authorization is required by some payers, most notably Medicaid and certain Medicare Advantage plans, before they will cover rosuvastatin.

What Documentation You Need

The prescribing provider submits a PA request that includes:

• Patient diagnosis (hyperlipidemia, ASCVD, or familial hypercholesterolemia)
• Recent lipid panel results with the date drawn
• 10-year ASCVD risk score (for primary prevention patients)
• Documentation of any statin intolerance or therapeutic failure if applicable
• Clinical rationale for rosuvastatin over atorvastatin, if the plan's preferred statin is atorvastatin

Timeline

New York Insurance Law requires health plans to respond to prior authorization requests within three business days for non-urgent requests. Urgent requests must be processed within 24 hours. If denied, you have the right to an expedited appeal.

Avoiding PA on Commercial Plans

Most commercial plans do not require PA for generic rosuvastatin. If your plan does, switching from brand Crestor to generic rosuvastatin often bypasses the PA entirely, since plans apply PA primarily to brand-name drugs with available generics.

Pharmacy Options in New York

New York has a dense pharmacy network. Patients can fill rosuvastatin at retail chains, independent pharmacies, mail-order services, or 503A compounding pharmacies.

Retail Pharmacies

CVS, Walgreens, Rite Aid, and Duane Reade locations across the five boroughs and upstate New York stock generic rosuvastatin. Most will fill a prescription same-day. E-prescribing from telehealth providers is accepted at every major chain.

Mail-Order Pharmacies

Mail-order services like Express Scripts, OptumRx, and Amazon Pharmacy typically offer 90-day supplies at a lower per-unit cost than 30-day retail fills. For a maintenance medication like rosuvastatin that patients take indefinitely, mail-order can save $50 to $100 annually.

503A Compounding Pharmacies

New York licenses 503A compounding pharmacies under strict state board oversight. These pharmacies can compound rosuvastatin into alternative dosage forms (such as a suspension for patients who cannot swallow tablets) based on a patient-specific prescription. Compounded rosuvastatin is not substitutable for commercial tablets and is typically more expensive, so it is reserved for patients with a documented clinical need. The New York State Board of Pharmacy requires 503A facilities to follow USP 795 compounding standards.

Transferring a Prescription to New York

If you are relocating to New York from another state, your existing pharmacy can transfer your rosuvastatin prescription to a New York pharmacy. The receiving pharmacist contacts your previous pharmacy to verify the prescription details. Controlled substances have transfer restrictions, but rosuvastatin is not a controlled substance, so transfers are straightforward. Allow 24 to 48 hours for the transfer to process.

Rosuvastatin Dosing and Monitoring After Access

Once you have your prescription filled, knowing the dosing tiers and follow-up schedule matters for long-term success.

Dose Selection

The 2018 AHA/ACC guideline categorizes statin therapy by intensity [2]:

• Moderate intensity: rosuvastatin 5 mg to 10 mg daily (expected LDL-C reduction 30% to 49%)
• High intensity: rosuvastatin 20 mg to 40 mg daily (expected LDL-C reduction 50% or more)

Most adults aged 40 to 75 with an ASCVD risk score of 7.5% or higher qualify for moderate-to-high intensity therapy. The JUPITER trial enrolled adults with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP above 2 mg/L) and still demonstrated significant benefit with rosuvastatin 20 mg [1].

Monitoring Schedule

After initiation, check a fasting lipid panel and hepatic function at 4 to 12 weeks. If the patient tolerates the medication and LDL-C is at target, labs can move to every 3 to 12 months depending on clinical stability. Report muscle pain, dark urine, or unexplained weakness immediately, as these may signal rhabdomyolysis, a rare but serious adverse effect occurring in approximately 1.6 per 100,000 patient-years according to FDA post-marketing data [3].

Special Populations

Patients of Asian descent may have higher rosuvastatin plasma concentrations due to pharmacogenomic differences in OATP1B1 transporter activity. The FDA label recommends a starting dose of 5 mg in this population [3]. Patients with eGFR below 30 mL/min/1.73 m² should not exceed 10 mg daily unless closely monitored by a nephrologist.

How Long Until You Receive Rosuvastatin in New York

The timeline from deciding to get rosuvastatin to having pills in hand depends on your starting point.

For patients with recent labs and no PA requirement: a telehealth visit can result in a prescription sent to your pharmacy within hours. Most pharmacies fill generic rosuvastatin the same day. Total time: under 24 hours.

For patients needing new labs: add 2 to 5 business days for a blood draw and result turnaround. Quest Diagnostics and Labcorp locations throughout New York typically return lipid panel results within 1 to 2 business days.

For patients requiring prior authorization: add 1 to 3 business days after the provider submits the PA request. In the worst case (new labs plus PA), expect roughly 7 to 10 business days from initial visit to filled prescription.

"Statin therapy should not be delayed in high-risk patients. If prior authorization creates a barrier, providers should consider prescribing a formulary-preferred statin as a bridge while the PA processes," according to the 2018 AHA/ACC cholesterol guideline writing committee [2].

"For patients with clinical ASCVD, maximally tolerated statin therapy is the foundation of lipid management," states the Endocrine Society's 2020 clinical practice guideline on lipid management [5].